



Recent Advances in Peptide-Based Vaccines

Guest Editor:

Dr. Hussin Rothan

Department of Biology, Georgia
State University, Atlanta, GA
30302, USA

Deadline for manuscript
submissions:

closed (15 October 2021)

Message from the Guest Editor

Using entire organism-based vaccines has various potential disadvantages such as induction of allergy, autoimmunity, and antibody-dependent enhancement in some cases. On the other hand, peptide-based vaccines are more specific, safe, and cost-effective. These peptides can be engineered and manufactured to resemble specific immunogenic antigens of pathogenic agents. In addition, peptide-based vaccines have attracted much interest in the development of novel vaccines to treat certain chronic diseases such as Alzheimer's disease and cancer, providing protective responses and limiting the administration of therapeutics. However, peptide-based vaccines have a low immunogenic effect and therefore need potent immune-stimulating adjuvants and specialized delivery carriers such as nanoparticles or fused to immunogenic carriers.

This Special Issue focuses on the recent advances in peptide-based vaccines, including peptide identification, immunogenic effect and adjuvant agents, and selected delivery systems.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com